Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • blank2thisone blank2thisone Jul 31, 2014 3:05 PM Flag

    Repost!: $4.5 billion CF market....INSM; Arikayce = Blockbuster...Just around the corner!

    blank2thisone • Jul 23, 2014 11:12 AM Remove

    4 users liked this posts users disliked this posts 0
    Reply

    Repost !! Changing paradigm towards CF = market $ 4.5 billio !!!

    Changing the Paradigm in Cystic Fibrosis
    Abstract:
    As a rare disease, cystic fibrosis (CF) didn’t get much attention from the pharmaceutical industry, and as a result the outlook for patients was bleak—a lifetime of lung infections and a life expectancy that rarely extended beyond the mid-30s. That’s all changing now, as more than a half-dozen pharmaceutical and biotech companies have entered the race to develop better treatments, and even cures for CF.

    This ebook will examine the changing landscape in CF, with input from drug developers, patients, and physicians. It will look at the science behind the newest remedies for this disease, including ongoing efforts to identify and target genetic mutations that contribute to CF. And it will analyze the commercialization strategies companies are employing to make the most of this market—which is projected to grow from $695.6 million in sales in 2012 to almost $4.5 billion in 2019.

    Topics include:

    Major research programs underway at pharmaceutical giants such as Novartis and Pfizer, the latter of which is working with a $58 million research grant from the CF Foundation
    The race among smaller companies such as AbbVie, Insmed, and Kala Pharma to develop next-generation treatments
    The impact of a highly publicized but faulty rollout of Vertex Pharmaceuticals’ new CF drug

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Commercial Opportunities
      ● US
      : NTM Phase 2 data; Initiating Phase 3 trials in
      treatment refractory and broader NTM patient populations

      ● Europe
      : EMA Filing for CF and NTM in 2H 2014

      Changing the Paradigm in Cystic Fibrosis
      Abstract:
      As a rare disease, cystic fibrosis (CF) didn’t get much attention from the pharmaceutical industry, and as a result the outlook for patients was bleak—a lifetime of lung infections and a life expectancy that rarely extended beyond the mid-30s. That’s all changing now, as more than a half-dozen pharmaceutical and biotech companies have entered the race to develop better treatments, and even cures for CF.

      This ebook will examine the changing landscape in CF, with input from drug developers, patients, and physicians. It will look at the science behind the newest remedies for this disease, including ongoing efforts to identify and target genetic mutations that contribute to CF. And it will analyze the commercialization strategies companies are employing to make the most of this market—which is projected to grow from $695.6 million in sales in 2012 to almost $4.5 billion in 2019.

      Topics include:

      Major research programs underway at pharmaceutical giants such as Novartis and Pfizer, the latter of which is working with a $58 million research grant from the CF Foundation
      The race among smaller companies such as AbbVie, Insmed, and Kala Pharma to develop next-generation treatments
      The impact of a highly publicized but faulty rollout of Vertex Pharmaceuticals’ new CF drug

      Sentiment: Strong Buy

    • Thansk! This is the DD we need! Fact based.

      Sentiment: Strong Buy

 
INSM
27.38+0.28(+1.03%)Aug 3 4:00 PMEDT